Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 (Healthy Volunteers) Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

NCT06919796
View directory record Official record
Conditions
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Interventions
COMIRNATY®
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

NCT05594602
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Itraconazole, Carbamazepine, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

NCT04519437
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
REGN10933+REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 4, 2026, 4:55 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of SLV213 for the Treatment of COVID-19.

NCT06146374
View directory record Official record
Conditions
COVID-19
Interventions
Placebo for SLV213, SLV213
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of AV-001 in Healthy Subjects

NCT04737486
View directory record Official record
Conditions
Covid19-associated ARDS, Covid19, ARDS
Interventions
AV-001, Placebo
Drug · Other
Lead sponsor
Vasomune Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

NCT05004181
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions
BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
14
States / cities
Long Beach, California • San Diego, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

NCT04336410
View directory record Official record
Conditions
Coronavirus Infection
Interventions
INO-4800, CELLECTRA® 2000
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

NCT04679909
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AdCOVID, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Hialeah, Florida • Melbourne, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine

NCT05743335
View directory record Official record
Conditions
COVID-19, Infectious Disease
Interventions
JCXH-221, Placebo
Biological · Other
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
4
States / cities
Hallandale, Florida • Savannah, Georgia • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

dMAbs for Prevention of COVID-19

NCT05293249
View directory record Official record
Conditions
Healthy Volunteers
Interventions
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Combination Product · Drug
Lead sponsor
Pablo Tebas
Other
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of Orally Administered GS-441524 for COVID-19

NCT04859244
View directory record Official record
Conditions
COVID-19
Interventions
GS-441524
Drug
Lead sponsor
Copycat Sciences LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 4, 2026, 4:55 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pancoronavirus Vaccine Study in Healthy Adults

NCT06950177
View directory record Official record
Conditions
COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
Interventions
CoV-RBD-scNP-001 and 3M-052-AF
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

NCT05594615
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Midazolam, Rosuvastatin, Caffeine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

NCT04025580
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Flucelvax, Fluvirin, Fluzone High Dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

NCT05129475
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07321332/ritonavir, Ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

NCT05091723
View directory record Official record
Conditions
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
Interventions
Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

NCT04852978
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
casirivimab+imdevimab, Moderna mRNA-1273 vaccine
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Hialeah, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 4, 2026, 4:55 AM EDT
Completed No phase listed Observational

Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses

NCT04377100
View directory record Official record
Conditions
Anxiety, Healthy Volunteers
Interventions
Computer task questionnaires
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
2,962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT06568861
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

NCT06878170
View directory record Official record
Conditions
COVID-19
Interventions
RBM-001
Biological
Lead sponsor
Rock BioMedical, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 4, 2026, 4:55 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

NCT05078905
View directory record Official record
Conditions
COVID-19, Vaccination, Healthy Volunteer
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 4, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777
View directory record Official record
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 4, 2026, 4:55 AM EDT